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1. INTRODUCTION 
 
1.1 Epidemiology of uterine cancer 
Uterine cancer accounted for 233,300 new cases and 61,400 deaths worldwide in 
2005 1. It is the most common cancer of the female genital tract in developed 
countries, but there is more than 14-fold variation in the incidence between countries 
(Figure I) 2. In Norway, the reported rate is about 16 cases per 100,000 women per 
year, whereas rates in developing countries are generally lower than 5 per 100,000 1,3. 
Temporal incidence trends appear to differ by the timing of menopause. In Norway, the 
increasing incidence of postmenopausal uterine cancer contrasts with the declining 
rates observed in premenopausal women from 1953 to 1997 4. 
 Uterine cancer refers to different types of carcinomas of the uterine corpus. 
Epithelial, mesenchymal, mixed epithelial and mesenchymal and trophoblastic 
tumours can be distinguished according to the cells they originate from (Table I). 
Epithelial tumours originate from the cells of the endometrium, the inner lining of the 
uterus, and account for ca. 90% of all uterine cancers. 
 
 
 
 
 
Figure I: Incidence of cancer of the uterine corpus:  
 Age-standardized rates (world) per 100,000 (all ages) 5 
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Table I: Histological classification of malignant tumours of the uterine corpus 6 
 
Type I/Endometrioid adenocarcinoma  Typical 
 Villoglandular 
 Variant with squamous 
differentiation  
 Secretory variant 
 Ciliated variant 
 
Type II  Papillary serous 
 Clear-cell 
 
Mixed pattern cancers  Mixed adenocarcinoma 
 
1. Epithelial tumours/ 
    Endometrial carcinoma 
Rare subtypes  Mucinous 
adenocarcinoma 
 Squamous cell 
carcinoma 
 Transitional cell 
carcinoma 
 Small cell carcinoma 
 Undifferentiated 
carcinoma 
 
Endometrial stromal tumours  Endometrial stromal 
sarcoma, low grade 
 Endometrial stromal 
nodule 
 Undifferentiated 
endometrial sarcoma 
 
Smooth muscle tumours  Leiomyosarcoma 
 Smooth muscle tumour 
of uncertain malignant 
potential 
 
2.   Mesenchymal tumours 
Miscellaneous mesenchymal tumours 
 
 
Carcinosarcoma 
 
Adenosarcoma 
 
3.   Mixed epithelial and     
mesenchymal tumours 
Carcinofibroma 
 
 
Trophoplastic neoplasms  Choriocarcinoma 
 Placental site 
trophoplastic tumours 
 Epithelioid trophoplastic 
tumours 
 
4.   Gestational trophoplastic 
disease 
Molar pregnancies  Partial 
 Complete 
 Invasive 
 Metastatic 
 
As the vast majority of cancers of the uterine corpus are endometrial 
adenocarcinomas, we will hereafter refer to the disease as endometrial cancer. 
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1.2 Established risk factors of endometrial cancer 
Age: The majority of endometrial cancers are diagnosed in postmenopausal women. 
In 2007 the highest incidence rates in Norway were observed in the age group 70-74 
years (89 per 100,000). 
Age-specific incidence rate 2007 
Cancer of the uterine corpus
0,0
10,0
20,0
30,0
40,0
50,0
60,0
70,0
80,0
90,0
0-4 5-9
10
-14
15
-
19
20
-24
25
-
29
30
-34
35
-
39
40
-44
45
-49
50
-
54
55
-59
60
-
64
65
-69
70
-
74
75
-79
80
-
84 85
+
Age at diagnosis
Rate per 
100,000
 
Figure II: Age-specific incidence rates for cancer of the uterine corpus (2007) 7 
 
Reproductive factors: Early menarche and late menopause have consistently been 
associated with increased risk, probably due to a longer lifetime exposure to 
endogenous estrogen 8-11. Nulliparity is associated with increased risk. Risk decreases 
with increasing parity, with the most pronounced risk reduction following the first 
birth 12-15. However, studies of the impact of age at first or last birth have shown 
conflicting results 9-11;13;15. Endocrine disorders like the polycystic ovary syndrome 
(PCOS) are also associated with an increased risk of endometrial cancer. Chronic 
anovulation in those women leads to a lack of progesterone secretion normally present 
in the luteal phase. This constant estrogenic stimulation of the endometrium may 
cause endometrial hyperplasia and ultimately endometrial cancer 16. 
 
Exogenous hormone use 
Hormone replacement therapy (HRT): The main hypothesis in the development of 
endometrial cancer is exposure to unopposed estrogen (lack of progesterone) leading 
to increased mitotic activity, DNA replication and somatic mutations in endometrial 
cells 17. Menopausal treatment using estrogen unopposed by progesterone increases 
the risk of subsequent endometrial cancer in a dose-risk manner 18, and combined 
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regimens of estrogen and progesterone were introduced to prevent this side effect. 
Nevertheless, minor increases in risk have also been reported for the combined 
treatment 19;20. 
Combined oral contraceptives (COCs): The use of combined oral contraceptives has 
consistently been found to reduce the risk for endometrial cancer. Ever use is 
reported to be associated with a 30% lower risk with an approximately 10% decrease 
in risk per each year of use. The protective effect of COCs appears to last over 
several years after cessation 21-23. 
Tamoxifen: Clinical trials such as the National Surgical Adjuvant Breast and Bowel 
Project (NSABP) and British Tamoxifen Second Cancer Study Group have provided 
evidence that endometrial cancer risk is increased in women with breast cancer 
treated with Tamoxifen 24;25. Tamoxifen use has been associated with a two-fold 
increased risk for endometrial cancer that was also dependent on duration of the 
use 26. 
 
Obesity: Endometrial cancer was the first cancer that was related to obesity 27. 
Several cohort 28-34 and case-control studies 35-42 have confirmed a positive 
association of obesity with endometrial cancer risk. 
 
Diabetes mellitus: Diabetes type 2 has also been related to increased risk of 
endometrial cancer in both cohort 29;43;44 and case-control studies 40;45-51. 
 
Smoking: Smoking has been reported to reduce risk in many studies 52-55. The 
underlying mechanisms for the reduced risk associated with cigarette smoking are 
poorly understood and are probably not exclusively caused by lower body weight 
among smokers. 
 
Heredity: Approximately 5% of all endometrial cancers are caused by inherited 
susceptibility. The Lynch syndrome (hereditary nonpolyposis colorectal carcinoma 
syndrome, HNPCC) accounts for most hereditary cases. Women with HNPCC have a 
lifetime risk of 42% for endometrial carcinoma 56. 
 
1.3 Symptoms and diagnosis 
Endometrial cancer is often detected early, since bleeding is a symptom in the early 
stage of the disease. Abnormal bleeding is present in approximately 90% of the 
cases 57. Among postmenopausal women, any bleeding is considered a possible 
INTRODUCTION 
5 
symptom of endometrial cancer and should lead to diagnostic testing. The probability 
of endometrial cancer in postmenopausal women with vaginal bleeding is 5-10%, but 
the chances increase with age and risk factors 58. Pre- and perimenopausal women 
with abnormal bleeding should also be examined for endometrial cancer, particularly 
if they have other risk factors (obesity, hormone-replacement therapy, tamoxifen 
use). Vaginal discharge without bleeding may be another symptom, whereas 
abdominal pain and distension occur later, at an advanced stage of the disease. 
Diagnostic approaches include gynaecological examination, vaginal ultrasound and 
endometrial sampling by either a Pipelle de Cornier sampling device or curettage in 
order to obtain tissue for a histological diagnosis. A pelvic magnetic resonance 
imaging is best in order to evaluate the size of the tumour, myometrial invasion and 
involvement of the cervix. Intra-abdominal spread is assessed by an abdominal 
computer tomography scan (CT). A thoracic x-ray or CT is performed to assess 
extra-abdominal spread. 
 
1.4 Molecular basis of endometrial cancer 
The understanding of the molecular pathogenesis of endometrial cancer is still far 
from complete, although various molecular alterations have been identified. These 
advances in molecular biology have reinforced that malignant tumours seem to arise 
from an accumulation of inherited and somatic alterations in oncogenes, tumour 
suppressor genes and DNA repair genes. 
 
Oncogenes: Oncogenes are usually inactive, and activation stimulates cell division. 
Among proto-oncogenes, the k-ras gene has been extensively studied in endometrial 
cancer, with a reported frequency of point mutations in 10-37% 59. There is further 
evidence for k-ras mutations being an early event in the development of endometrial 
cancer as the mutation is also reported in endometrial hyperplasia. 
 Another proto-oncogene, Her-2/neu, a member of the tyrosine kinase family, is 
considered to play a role in cellular transformation and tumourigenesis. Over-
expression of Her-2/neu is reported in 10-20% of the cases, being more frequent in 
non-endometrioid tumours 59. 
 Mutations in PIK3CA, a catalytic subunit of PI3K, have been identified in 
24-36% of endometrial carcinomas and are coexisting with PTEN mutations 60. 
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Tumour suppressor genes: Tumour suppressor genes code for proteins inhibiting 
tumour growth. When mutated, they become inactive and growth is allowed. The 
tumour suppressor gene PTEN is the most frequently mutated gene in endometrial 
carcinoma and is an early event in carcinogenesis. Loss of PTEN activates the 
PI3K/AKT pathway leading to up-regulation of several factors involved in cell 
proliferation, cell survival and angiogenesis 61. Absence of functional PTEN leads to 
activation of the MAPK/ERK (mitogen-activated protein kinase/extracellular signal-
regulated kinase) pathway that is stimulated by growth factors 62. 
 The tumour suppressor gene p53 encodes a protein that contributes to cell 
cycle arrest by binding to transcriptional elements in DNA. Nuclear p53 induces cell 
cycle arrest at the G1/S checkpoint prior to DNA replication and at the G2/M 
checkpoint prior to mitosis. These arrests enable time for DNA damage repair and 
prevent accumulation of mutations. In cases where the DNA damage is beyond 
repair, it also promotes apoptosis 63. Cells with mutated p53 that have damaged 
DNA, will continue directly to the S-phase leading to further accumulation of 
mutations, ultimately leading to tumorigenesis 64. P53 mutations have been found in 
10-20% of endometrial carcinomas 65, while overexpression is present in about 
15-30% 66. 
 The tumour suppressor gene CDKN2A/p16 encodes the p16 protein which 
acts by blocking cell cycle progression through inhibition of the CyclinD-CDK4 
complex formation 67. In endometrial cancer, loss of protein expression varies from 
14-74% 68. 
 
Microsatellite instability (MSI): Microsatellites are simple repetitive DNA sequences 
distributed widely throughout the genome. Microsatellite instability is a result of an 
accumulation of mutations caused by defects in the mismatch repair genes (MMR) 
during replication. MSI was first detected in tumours from patients with HNPCC, but 
has also been found in sporadic endometrial cancer 69. 
 
Cell cycle regulation and proliferation: In endometrial carcinoma, both cell cycle 
stimulating and cell cycle inhibitory proteins show altered expression. The most 
frequent disruption of the cell cycle is at the G1/S restriction point before DNA 
replication. The G1/S regulators are oncogenes like cyclin D1, D2 and E, CDK4/6 
and tumour suppressor genes like p16, p21, p27 and the retinoblastoma protein. 
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Apoptosis: The normal cyclic variation in endometrial tissue seems to be regulated by 
apoptotic stimuli. In endometrial carcinoma, mutations in the apoptosis inhibitory 
gene Bax cause concomitant loss of Bax expression 70. The oncogene Bcl-2 encodes 
a protein that inhibits apoptosis, and its expression is reduced in endometrial 
carcinoma 70. 
 
Cell adhesion and invasion: The ability of cancer cells to invade the surrounding 
tissue and to establish growth of tumour cells in distant organs represents the final 
step of tumour progression and is dependant on the interaction of their cell surface 
with the microenvironment. Specific genetic alterations in cellular adhesion 
molecules, among them cadherins and catenins, have been shown to be important 
for tumour-stroma and tumour-vascular interactions. The -catenin gene product is 
involved in two biological pathways. One involves E-cadherin that takes part in cell-
cell adhesion and the transmission of anti-growth signals. In the second pathway, 
-catenin is released from its association with APC (adenomatous polyposis coli) 
tumour suppressor protein allowing its translocation to the nucleus, where it acts as a 
cofactor to induce expression of cyclin D1 and other genes involved in cell cycle 
progression 71. 
 
Steroid receptors: The endometrium contains estrogen and progesterone receptors. 
Estrogen induces endometrial cell proliferation and differentiation, and progesterone 
can antagonize this effect 72. 
 
Angiogenesis: Angiogenesis estimated by intra-tumour microvessel density (MVD) is 
a critical factor for the growth and spread of malignant tumours. Vascular endothelial 
growth factors (VEGF) are important regulators, where VEGF-A stimulates 
endometrial proliferation and tumour progression 73. 
 
1.5 Dualistic model of sporadic endometrial cancer 
A dualistic model of two types of endometrial carcinomas with distinctive histological 
and clinical features and molecular alterations has been established 74;75 (Figure III). 
Type I accounts for 80-90% of all endometrial cancers and have endometrioid 
(typical, villoglandular, with squamous differentiation, secretory or ciliated) features. 
These tumours develop from endometrial hyperplasia and are mostly well or 
moderately differentiated. Type II cancers represent 10-20% of all cases and have 
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serous or clear-cell features. They develop from atrophic endometrium and show no 
or very little estrogen and progesterone receptor expression. There are several other 
histological subtypes of endometrial cancers, but they are rare (Table I). The clinico-
pathologic differences between type I and type II cancers are paralleled by specific 
gene alterations, despite some overlap. Inactivation of the PTEN tumour suppressor 
gene is the most common genetic defect in type I carcinomas. Other genetic 
mechanisms involved in type I include microsatellite instability, mutations of k-ras, 
PIK3CA and the 1-catenin gene. Conversely, genetic abnormalities in type II include 
p53 mutation, Her-2/neu amplification and inactivation of p16 76. 
 
 
A B 
 
Figure III: The prototypes of the dualistic model of endometrial carcinoma. A: Endometrioid 
adenocarcinoma (type I). B: Serous papillary adenocarcinoma (type II). Adapted 
from Alfsen C., Neoplasier I Uterus. Kurs O-23558 
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1.6 Staging of endometrial cancer 
Endometrial cancer is surgically staged according to The International Federation of 
Gynecology and Obstetrics (FIGO). Recently, a new staging system for endometrial 
cancer was published 77. Surgical staging is based on total hysterectomy, bilateral 
salpingo-oophorectomy, peritoneal cytology and lymph node sampling. 
 
Table II: Staging of endometrial cancer (FIGO) 
 
Stage Features  
I Tumour confined to the uterine corpus, not involving the uterine serosa  
IA No or  50% myometrial invasion 
 
IB Myometrial invasion > 50% 
 
II Tumour invasion of cervical stroma but no extension beyond the 
uterus 
 
III Local and/or regional spread of the tumour  
IIIA Tumour invasion of the uterine serosa and/or the adnexae 
 
IIIB Vaginal and /or parametrial involvement 
 
IIIC Metastases to the pelvic and/or para-aortic lymph nodes  
IIIC1 Positive pelvic nodes  
IIIC2 Positive para-aortic nodes with or without positive pelvic nodes  
IV Tumour involvement of the bowel and/or bladder mucosa and/or 
distant organs 
 
IVA Tumour involvement of the mucosa of the bowel and/or bladder 
 
IVB Distant metastases, including intra-abdominal metastases and/or 
inguinal lymph nodes 
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The purpose of surgical treatment is i) to remove malignant tissue for therapeutic 
purposes and ii) to determine the presence of extrauterine disease for treatment 
decisions. Positive peritoneal cytological findings are no longer a criterion for disease 
upstaging, but the procedure is still recommended due to the independent prognostic 
value when combined with other poor prognostic factors. The depth of myometrial 
invasion and the extent of extrauterine disease have all been incorporated into the 
FIGO staging system. However, preoperative assessment is important in order to 
tailor treatment and to choose the optimal institution for treatment. 
 
1.7 Treatment 
Hysterectomy with bilateral salpingo-oophorectomy is the first step in the treatment of 
endometrial cancer. There is an ongoing debate with regard to the most appropriate 
surgical approach (laparotomy, laparoscopy or robotic techniques). The most 
debated issue in endometrial cancer management, however, is the lymph node 
dissection in women with low grade and early stage disease. Based on FIGO stage 
and histological grade of the tumour, patients are classified as being at low, 
intermediate or high risk for extrauterine spread, lymphatic metastasis and 
recurrence (Table III). Two randomized studies trials could not report a survival 
benefit for intermediate risk patients undergoing lymphadenectomy 78;79. However, 
the percentage of nodal positivity was low in both studies, and nodal dissection was 
restricted to the pelvis. There also remains controversy regarding the extent of 
retroperitoneal lymph node dissection. In patients with positive pelvic nodes 40-57% 
will also have para-aortic metastasis 80;81. However, in GOG (Gynecologic Oncology 
Group) #33, 35% of the patients showed positive para-aortic spread without the 
presence of pelvic node involvement 82. Thus, lymphadenectomy should include 
para-aortic nodes. In Norway, sampling of lymph nodes and evaluation of DNA ploidy 
are recommended for intermediate risk patients. In high risk patients, a thorough 
lymphadenectomy of the pelvic and para-aortic region is performed. Different surgical 
management is needed for type II endometrial cancers. Given the high likelihood of 
extrauterine disease, a thorough lymphatic dissection and omentectomy is 
recommended in women with such tumours 83. Still, evidence from randomized trials 
regarding a benefit from this more extensive treatment of type II cancers is lacking. 
Indications for radiotherapy are generally in the adjuvant setting with the goal 
to treat the pelvic lymph node regions that might contain microscopic disease, as well 
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as the central pelvic region including the upper vagina. There is general consensus 
that adjuvant radiation therapy can be omitted in low risk women with FIGO stage 1A 
and grade 1 or 2 tumours. However, more recent large, randomized trials (PORTEC, 
GOG-99, ASTEC/EN.5) 84-86 failed to show a survival benefit of adjuvant pelvic 
radiotherapy for all intermediate or high-risk patients with stage I endometrial cancer. 
Most women with intermediate risk will therefore not receive adjuvant treatment on 
the condition that they are appropriately staged. In cases of advanced disease, 
chemotherapy is now the standard therapy as many high risk patients will have 
extrapelvic disease at the time of diagnosis. The combination of paclitaxel, epirubicin 
and carboplatin (TEC) or carboplatin and paclitaxel (TC) are the most commonly 
used regimes. The role of the combination of adjuvant chemotherapy alone, the 
combination of chemotherapy and radiotherapy, the best chemotherapeutic regimen 
and the identification of subgroups of patients that may benefit from adjuvant therapy 
still deserve further research. 
Primary hormone therapy can be considered in patients with advanced 
disease who are not eligible for other treatment options or with relapse with distant 
metastasis. Important positive predictive factor for response is the presence of 
estrogen and progesterone receptors with 72% response rate in receptor positive 
tumours. Progestagens have been the cornerstone of the hormone therapy for 
endometrial cancer, and the ideal dose considered is 200 mg of 
medroxyprogesterone acetate 87. 
 
Table III: Risk stratification of early stage endometrial cancer 83 
Risk Stages Risk and localisation of relapse 
Low risk Stage IA (grade 1,2) 5-7%; mostly local 
Intermediate risk Stage IA (grade 3) 
Stage IB (grade 1,2) 
10%; mostly local 
High risk IB (grade 3) 
Papillary serous or clear-cell histology 
25%; pelvis and distant disease 
 
 
1.8 Prognosis 
Diagnosis of endometrial cancer at an early stage of disease is usual due to the 
presence of symptoms at an early stage. Overall, the five year survival rate is around 
83%. The prognostic impact of age, histological subtype, histological grade and 
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surgical FIGO stage is well-established 83. The FIGO stage reflects the 5-year 
survival around 85% for stage I, 75% for stage II, 45% for stage III and 25% for stage 
IV 88-90. The favourable survival in early stage cancers may also reflect the problem of 
onset confounding as tumours diagnosed at early stage may not be likely to 
progress. Survival in patients with type II cancers is decreased compared to patients 
with well-differentiated adenocarcinomas of the type I category. 
 
1.9 Prognostic tumour markers 
In order to further improve treatment and follow-up, ploidy, hormone receptor status 
and a wide range of other molecular markers have been extensively studied for 
prognostic impact 91. Diploid tumours are often well-differentiated and have been 
shown to correlate with longer median survival. Still, only a few reports have included 
other prognostic factors and the true clinical value of this method remains to be 
validated. Expression of p53 and alteration of p16 seem to be associated with 
unfavourable prognosis, and there are other potentially prognostic factors like steroid 
receptor expression, PTEN alterations, Her2/neu-, Ki-67- and E-cadherin expression. 
Angiogenesis is a critical factor for tumour growth and spread. Thus, increased intra-
tumour microvessel density (MVD) and overexpression of VEGF-A (vascular 
endothelial growth factor) are markers for tumour proliferation and progression and 
can result in vessel defects and hematogenous spread. Lymphatic vessel invasion 
and blood vessel invasion seems to be associated with an aggressive phenotype and 
a worsened prognosis even in the absence of documented lymph node 
metastasis 92;93. However, studies of the prognostic impact of these biologic markers, 
and their utility in routine diagnostic remain to be settled. 
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2. OBJECTIVES OF THIS THESIS 
 
The major objective of this thesis was to study different aspects of the association of 
obesity with endometrial cancer. It is still not clear whether the effect of body mass 
index (BMI) on endometrial cancer risk displays a linear relation or if there is a 
threshold effect leading to higher risk for obese women (BMI 30 kg/m2) only 94. The 
relative impact of high BMI categories has not been extensively studied, and in most 
cohort studies calculation of BMI was based on self-reported weight and height. Only 
few studies have addressed a possible differential impact of BMI on endometrial 
cancer risk before and after menopause, with conflicting results 30;32-34. We have 
therefore studied the association of increments of body mass index with the risk of 
endometrial cancer in all women and separately in women younger than or older than 
55 years of age. 
 Despite the growing evidence that the metabolic syndrome, including obesity 
and obesity-related insulin resistance, is implicated in endometrial carcinogenesis, it 
is not known whether related factors, such as serum lipids and lipoprotein levels, are 
associated with the risk of this cancer. A number of risk factors (e.g. obesity and 
exogenous estrogen exposure) appear to interact with the metabolism of lipids. Only 
two prior epidemiological studies of sufficient size have assessed the association of 
serum lipids with endometrial cancer risk 95;96 and they showed conflicting results. We 
therefore studied whether the obesity-related factors, serum lipids and lipoprotein 
levels, were associated with subsequent risk of endometrial cancer. 
The impact of BMI may vary across different histological subtypes of 
endometrial cancer, and it has been hypothesized that the positive association of 
obesity may be restricted to estrogen dependent type I cancers. The development of 
clear-cell and serous tumours (type II) seems not to be related to estrogen 
exposure 74. Three population-based studies have addressed whether obesity is 
differentially associated with histological subtypes of uterine cancer, but with 
inconsistent results 28;32;97. We compared the association of BMI with the risk of 
uterine cancer as a single entity, with all endometrial cancers and with the risk of 
endometrioid adenocarcinomas.  
 The incidence rates of endometrial cancer have constantly increased over the 
last decades. In Norway, repeated health surveys have documented an increase in 
both mean BMI and in the prevalence of obesity in the female population (Figure IV). 
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By analyzing period and cohort related patterns, we wished to describe the 
endometrial cancer epidemic and evaluate which factors may have had an impact on 
the incidence trends. Monitoring the incidence is important for healthcare planning 
purposes and is an integral component of cancer control programmes. Surveillance 
of incidence may also provide indicators of risk factors of the disease. Prediction of 
the future number of cases is therefore of great interest to society, also in order to 
develop preventive strategies. Based on the observed trends in Norway we provided 
two scenarios of the future burden of endometrial cancer and predicted the number 
of new cases and incidence rates in 2015 and 2025 by using these models. 
 
Figure IV: Changes in body mass index in 40 year old women, Norway 1989-1999. 
 Adapted from Norwegian Institute of Public Health, www.fhi.no 
 
 
More specifically, we aimed at the following: 
 
Paper I: To study the impact of increments of BMI, diabetes and smoking on the risk 
of endometrial cancer  
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Paper II: To study the association of serum lipids and lipoprotein levels with 
subsequent risk of endometrial cancer 
 
Paper III: To study the impact of BMI on subgroups of uterine cancer 
 
Paper IV: To study endometrial cancer incidence trends in Norway during 1953-2007 
according to calendar period and birth cohort and to predict future trends in incidence 
rates until 2027 
 
MATERIAL AND METHODS 
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3. MATERIAL AND METHODS 
 
3.1 Study design and study population 
Paper I-III: Nord-Trøndelag Health Study (HUNT) 
In our studies we used data from the Nord-Trøndelag Health Study 1 (HUNT 1) and 2 
(HUNT 2). In both surveys every individual resident in the county at the age of 20 and 
older was invited to participate. 
 HUNT 1 was conducted between 1984 and 1986 and was the largest health 
survey ever performed in Norway. It was primarily designed to cover studies on 
hypertension, diabetes, lung disease and quality of life. The invitation letter and a 
questionnaire were mailed to each participant (appendix). At the examination the 
participants received a second questionnaire that included items on physical activity, 
alcohol use, diabetes and smoking (appendix). The second questionnaire was to be 
filled in at home and returned in a pre-stamped envelope. 
 The second Nord-Trøndelag Health Study in 1995-97 (HUNT 2) was partly a 
follow-up study of HUNT 1. HUNT 2 comprised, however, a larger scientific program 
and aimed at the large public health issues like cardiovascular disease, diabetes, 
obstructive lung disease, osteoporosis and mental health. The invitation letter was 
sent by mail, attached to a three-page questionnaire (appendix) and an information 
folder. The questionnaire was to be completed prior to the examination and returned 
at attendance to the examination site. A second questionnaire (appendix) was 
handed out at the screening site and should be completed and returned in a pre-
stamped envelope. A wide range of topics was addressed in questionnaire 1 and 2 
covering health issues, personal environment, personal habits like food intake and 
drug use, family medical histories and health services consumption. 
 A detailed description of the study populations used in paper I-III is given in 
figures V-VII. 
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Figure V: Study population paper I (HUNT 1) 
 
 
 
 
 
Figure VI: Study population paper II (HUNT 2) 
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Figure VII: Study population paper III (HUNT 1) 
 
 
Paper IV: The Cancer Registry of Norway 
The Cancer Registry of Norway, Institute of Population-based Cancer Research, was 
established in 1951. It is one of the oldest national cancer registries in the world. All 
medical practitioners in the country are instructed by law to notify new cancer cases to 
this registry. Additionally, all pathological laboratories send copies of their reports to 
the Cancer Registry. To further achieve a high degree of completeness and data 
quality, the material is matched against the Register of Deaths at Statistics Norway. 
The cancer registration system is in concordance with international standards, with 
completeness estimated at around 98% overall and over 99% for cancers of the 
corpus uteri for the years 2001-2005 98. Such a high figure is considered the result of 
the efficient multiple source reporting and routine trace-back conducted by the 
registrars of the Cancer Registry. 
 In 1970 all topography codes were converted to ICD-7 (International 
Classification of Diseases, 7th revision) and to ICD-10 in 1993. The morphology of 
Invited 
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Eligible to the study 
N=38,260 women 
Not returned 
Study population 
N=36,755 
Eligible 
N=92,936 
Uterine cancer 
(ICD-7: 172) 
N=263  
End of follow-up December 31st, 2005
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N=1,088
BMI not 
available 
N=417
Non-Participants 
N=26,796 
Dead/moved 
N=1,258 
Endometrial cancer 
N=224 
Endometrioid 
adenocarcinoma 
N=166 
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cancers diagnosed before 1993 were classified according to the Manual of Tumour 
Nomenclature and Coding (MOTNAC), a 4-digit system. After 1993 tumours were 
classified according to ICD-O-2, a 6-digit code for morphology and grade of 
differentiation. 
 
3.2 Data access and ethics 
The study was approved by the Regional Committee for Medical Research Ethics, 
the Norwegian Directorate of Health and by the Norwegian Data Inspectorate.  
 
3.3 Follow-up 
Follow-up of women in the HUNT study with regard to development of endometrial 
cancer was performed by linkage to the Cancer Registry of Norway. The unique 11-
digit identity number of Norwegian citizens enabled individual linkage of study 
participants to information on uterine cancer recorded at the Cancer Registry. All 
women diagnosed with uterine cancer in the study population (International 
Classification of Diseases, 7th revision, ICD-7, code 172) were identified, based on 
mandatory reporting from all pathological laboratories in Norway to the Cancer 
Registry. Time of follow-up was calculated from date of clinical examination until the 
date of uterine cancer or any other cancer (except basal cell carcinoma), emigration, 
death or to the end of follow-up (censoring), whichever occurred first. 
 
3.4 Study factors 
Dependent variables 
Time from study inclusion to diagnosis of uterine cancer was used as dependent 
variable in our analyses. In the following, we give a detailed description of the 
dependent variables in the presented papers. 
 
Paper I: Time from date of study inclusion (clinical examination in HUNT 1) until the 
date of uterine cancer, censoring or to the end of follow-up at December 31st, 2002, 
was the dependent variable. In separate analyses among women less than 55 years 
of age, time from date of clinical examination until uterine cancer before the age of 55 
or until censoring at the age of 55 was used as dependent variable. Only women less 
than 55 years old at study inclusion were included in this analysis. 
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Paper II: In this study, time from date of clinical examination (in HUNT 1) until the 
date of uterine cancer, censoring or to the end of follow-up at December 31st, 2005, 
was the dependent variable. 
 
Paper III: In this study, time from date of clinical examination (in HUNT 1) until the 
date of uterine cancer, censoring or to the end of follow-up at December 31st, 2005, 
was the dependent variable. In separate analyses we used time to i) endometrial 
cancer (ICD-O-2 codes 8380/3, 8570/3, 8262/3, 8382/3, 8383/3, 8480/3, 8441/3, 
8310/3, 8323/3, 8070/3, 8120/3, 8041/3, 8020/3 and MOTNAC codes 8017, 8143, 
8144, 8145, 8147, 8447, 8563, 8565, 8567, 8573, 9113) and ii) endometrioid 
adenocarcinoma (ICD-O-2 codes 8380/3, 8570/3, 8262/3, 8382/3, 8383/3 and 
MOTNAC codes 8143, 8144, 8145) as dependent variable. 
 
Independent variables 
Exposure data was collected from two sources: Clinical data were obtained at the 
physical examination at study inclusion. In addition, self-administered questionnaires 
provided information on lifestyle and demographic characteristics. 
 
Age: Age was defined at age at syntax date, which was the date for control of 
punched data, performed 7 to 21 days after the date of clinical examination. Since 
age is a strong determinant of endometrial cancer, it is important to control for age in 
analyses of potential risk factors. We included age in the Cox regression model using 
10-year categories. In paper III, we adjusted for age by using age as the time axis in 
the Cox model. 
 
Body mass index (BMI): BMI was calculated as weight divided by height squared 
(kg/m2). Height and weight were measured when the participants were wearing light 
clothes without shoes. Height was recorded to the nearest 1.0 cm and weight to the 
nearest 0.5 kg. BMI was categorized as <20, 20-24, 25-29, 30-34, 35-39, and 40 
kg/m2 in paper I and III and categorized as <25, 25-29, 30-39, or 40 kg/m2 in paper 
II. 
 
Blood lipids: Blood sampling in HUNT 2 was done whenever subjects attended, i.e. 
non- fasting or “random” state. At baseline, 7.5 ml of whole blood was drawn from 
each participant, and serum was separated by centrifuging at the screening site. 
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Serum lipids were measured at the Central Laboratory of Levanger Hospital in Nord 
Trøndelag County, on the same day or within two to three days of serum sampling. 
Total serum cholesterol, HDL cholesterol and triglycerides were measured 
enzymatically, using an autoanalyser (Hitachi 911, Hitachi, Mito, Japan) and reagents 
from Boehringer Mannheim (Mannheim, Germany). HDL cholesterol was measured 
after precipitation with phosportungsten and magnesium ions. The day-to-day 
coefficients of variation were 1.3-1.9% for cholesterol, 2.4% for HDL cholesterol and 
0.7-1.3% for triglycerides. Non-HDL cholesterol was calculated as HDL cholesterol 
subtracted from total cholesterol, and LDL cholesterol was calculated using the 
Friedewald equation 99. In the statistical analyses, we used quartiles of each serum 
lipid, based on the distribution in the cohort as a whole. In a separate analysis of 
triglycerides we also used the following categories: < 1.0, 1.1-1.5, 1.6-2.0, 2.1-3.0, 3.1-
4.0, >4.0 mmol/l and treated them as a continuous variable in the data analysis. 
 
Diabetes: Information on diabetes mellitus was assessed from the self-administered 
questionnaire at baseline (yes/no). 
 
Smoking: Smoking status was coded as never, former, current or missing.  
 
Other possibly confounding variables 
Marital status: Marital status was classified as married, unmarried, widow or 
divorced/separated. 
 
Educational level: Level of education was classified as <10 years, 10-12 years, >12 
years or missing. 
 
Waist and hip circumference: Waist and hip circumference were measured only in 
HUNT 2 with a steel band to the nearest 1.0 cm with the participant standing and with 
the arms hanging relaxed. The waist circumference was measured horizontally at the 
height of the umbilicus, and the hip circumference was measured likewise at the 
thickest part of the hip. We used quartiles of both these measurements and the waist-
hip ratio in paper II. 
 
Blood pressure: Blood pressure was measured by specifically trained nurses using a 
Dinamap 845XT (Critikon) based on oscillometry. Cuff size was adjusted to the arm 
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circumference. Blood pressure was measured three times, and the mean of the 
second and third systolic and diastolic blood pressures were used in this study. Blood 
pressure 140/90 mmHg was classified as hypertension. 
 
Alcohol: Alcohol drinking was categorized as 0, 1-4, 5 times during the last two 
weeks, total abstainer or missing. 
 
Physical activity: Information on physical activity (i.e. walking, skiing, swimming or 
other sports) was obtained by questions on frequency (0, <1, 2-3 and > 4 times per 
week), average duration (<15, 15-30, 30-60 and >60 min) and intensity (light, 
moderate and vigorous). We utilized this information to calculate a summary score of 
physical activity. Based on this score the participants were divided into five 
categories (no activity, low, moderate, high activity and missing). 
 
3.5 Statistical analysis 
We used the Cox proportional hazards model to examine the association between 
relevant exposure variables and endometrial cancer risk. This statistical regression 
procedure is a popular and robust mathematical model, often used to analyse data 
where survival time is available and where follow-up is censored. However, use of 
the Cox model requires that the hazard ratio is constant over time. We used analyses 
of Schoenfeld residuals in order to test the proportional hazard assumption. We 
estimated the age-adjusted relative risks (RR) of the relevant exposure variables with 
95% confidence intervals. Since the risk of endometrial cancer strongly depends on 
age, we included age and the relevant exposure variables as independent variables 
in the regression model and individual number of person-years as the dependent 
variable. Multivariable analyses were conducted to assess potential confounding by 
other factors for which we had information. Statistical analyses were performed using 
the SPSS statistical package in paper I (version 14.0) and paper III (version 16.0). 
We used STATA statistical package, version 10.0, in paper II. 
 The statistical analyses in paper IV were performed by Freddie Bray, MSc, 
PhD at the Cancer Registry of Norway. The model analysis was performed using the 
APC functions available in the library Epi in R. STATA was used for data 
management and plotting of the observed trends. 
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4. SYNOPSIS OF THE PRESENTED STUDIES 
 
Paper I: 
Body mass, diabetes and smoking and endometrial cancer risk: a follow-up 
study 
The incidence of endometrial cancer is increasing and obesity has been identified as a 
major risk factor. It is uncertain if there is a linear positive association of BMI (body 
mass index) with endometrial cancer risk. 
 We prospectively examined the association of body mass, diabetes and 
smoking with the risk of endometrial cancer in a cohort of 36,761 Norwegian women 
during 15.7 years of follow-up. 222 incident cases of endometrial cancer were 
identified by linkage to the Norwegian Cancer Registry. In multivariable analyses there 
was a strong and consistent increase in endometrial cancer risk with increasing BMI 
(p-trend <0.001). Compared to the reference (BMI 20-24), the adjusted relative risk 
(RR) was 0.53 (95% CI: 0.19-1.47) for BMI <20, 4.28 (95% CI: 2.58-7.09) for BMI of 
35-39, and 6.36 (95% CI: 3.08-13.16) associated with BMI 40. Women with known 
diabetes at baseline were at three-fold higher risk (RR 3.13, 95% CI: 1.92-5.11), 
compared to women without diabetes, and women who reported current smoking at 
baseline were at reduced risk compared to never smokers (RR 0.55, 95% CI: 0.35-
0.86). 
 We found a strong linear positive association of BMI with endometrial cancer 
risk, and a strongly increased risk among women with diabetes. The results suggest 
that any increase in body mass in the female population will increase endometrial 
cancer incidence. 
 
Paper II: 
Serum lipids and endometrial cancer risk: Results from the HUNT-II study 
Obesity is a major risk factor for endometrial cancer. Still, the association of obesity-
related metabolic factors, such as serum lipids and lipoprotein levels, is unclear. 
 We prospectively examined the association of serum levels of triglycerides, 
total cholesterol, LDL cholesterol, non-HDL and HDL cholesterol with endometrial 
cancer risk among 31,473 women. During nine years of follow-up, 100 cases of 
endometrial cancer were identified by linkage to the Cancer Registry of Norway. 
There was a positive association of serum triglyceride levels with endometrial cancer 
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risk. Comparing the highest to the lowest quartile of triglycerides, the age-adjusted 
hazard ratio was 2.34 (95% CI: 1.04-5.28), and further adjustment for body mass 
index (BMI) attenuated the association (hazard ratio 1.79, 95% CI: 0.79-4.05). For 
total serum cholesterol, LDL cholesterol and HDL cholesterol there were no 
associations with endometrial cancer risk, either without or after adjustment for BMI. 
 Serum triglyceride levels were positively associated with the risk of 
endometrial cancer, and some of the association appears to be attributable to 
obesity. Apart from higher estrogen levels produced in adipose tissue, mechanisms 
more specifically related to triglycerides may also be involved in endometrial cancer. 
Further prospective studies on this subject are needed to better understand the 
association of blood lipids with endometrial cancer risk. 
 
Paper III: 
The impact of BMI on subgroups of uterine cancer 
Obesity increases uterine cancer risk, but the impact may be limited to endometrioid 
adenocarcinomas. We followed 36,755 women for 17.8 years and found that BMI 
was positively associated with uterine cancers as a whole, with a particularly strong 
association for endometrioid adenocarcinomas. Compared to the reference (BMI 20-
24), the age-adjusted relative risk for BMI 40 was 6.7 (95% CI: 3.4-13.4) for all 
uterine cancers and 8.3 (95% CI: 4.1-16.7) for endometrial cancer. The 
corresponding estimate for endometrioid adenocarcinomas was 11.1 (95% CI: 5.2-
23.8). 
 
Paper IV: 
Endometrial cancer incidence trends in Norway during 1953-2007 and 
predictions for 2008-2027 
Endometrial cancer is the most common cancer of the female genital tract in Western 
countries. Monitoring the incidence is important for health care planning and the 
identification of risk factors.  
 We present an age-period-cohort analysis of incidence trends of endometrial 
cancer in Norway from 1953 to 2007 and compare the incidence trends with those in 
three other Nordic countries. Based on the observed trends we have predicted 
endometrial cancer rates in Norway in 2015 and 2025.   
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In women at postmenopausal age (55 years), the annual incidence increase was 
2.1% (95% CI: 0.9%, 3.4%) from 1988 to 1997 and 1.7% (95% CI: 0.6%, 2.8%) from 
1998 to 2007. In younger women, there was an annual reduction of 0.6% (95% CI: 
-2.3%, 2.2%) from 1988 to 1997, followed by an annual increase of 1.7% (95% CI: 
-0.4%, 3.9%) from 1998 to 2007. The secular changes are likely to reflect both cohort 
and period effects. Our prediction estimates by 2025 suggest an incidence increase 
in the range of 50% to 100%, relative to the observed incidence in 2005. 
 There has been a strong and consistent incidence increase in endometrial 
cancer in the Nordic countries over the last 50 years. The increase has been most 
pronounced in postmenopausal women, but in the last decade, rates have increased 
also in women younger than 55 years. The prediction for the next 20 years suggests 
that endometrial cancer rates will dramatically increase unless effective preventive 
strategies are implemented. 
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5. DISCUSSION 
 
The discussion of the results will address two different aspects of this work 
1.) Methodological considerations 
2.) Obesity and endometrial cancer - Proposed mechanisms 
 
5.1 Methodological considerations 
An epidemiological study can reflect the true effect of an exposure on development of 
disease, but the findings may also have alternative explanations. The estimated 
effect may be attributed to chance or to systematic errors that also influence the 
association between exposure and disease. There are three types of errors that have 
to be considered. These include bias in the selection of study subjects to inclusion or 
follow-up, information bias and confounding. 
 
5.1.1 The role of selection bias 
Selection bias results from skewed selection to participation or follow-up. Selection 
bias occurs when the relationship between the exposure and the disease is different 
from those in the study than for those not in the study 100. 
Participation in HUNT: Even if the participation rate in HUNT was fairly high 
compared to most other studies in Norway and abroad 101, there is still potential 
selection bias. The participation was highest among middle-aged women, among 
women who were married and among those living in small municipalities. However, a 
non-participation study in the HUNT 1 study could not find evidence of selection to 
participation with regard to health measures in younger age groups 102. Elderly non-
participants had, however, increased mortality and morbidity compared to the 
participants. Endometrial cancer is strongly associated with age. The higher rate of 
non-participation among older women may have caused an underestimation of the 
true incidence in this age group and thereby an underestimation of the effect of age 
on endometrial cancer risk. However, the impact of age was not a major objective of 
our study. If obese women, in particular among the elderly women, are 
underrepresented in our study, the impact of BMI may be underestimated. 
Selection to inclusion in our study sample: Women with prevalent cancer of any site, 
except basal cell carcinoma, were excluded from our study sample, since the 
association of the exposure variables (BMI, blood lipids) with endometrial cancer in 
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women with prevalent cancer may differ from the general population of women. 
Women with a previous cancer may also have a higher risk of endometrial cancer 
later in life, in particular women with colon cancer caused by the hereditary 
nonpolyposis colorectal carcinoma syndrome (HNPCC). Hence, exclusion of women 
with prevalent cancer may have underestimated the true incidence of endometrial 
cancer. It remains unclear whether exclusion of women with prevalent cancers has 
caused biased estimates of the association of BMI with endometrial cancer. 
 A relatively high proportion of the women in HUNT 1 did not respond to the 
questionnaire including information on smoking, alcohol use and physical activity. 
Response was about 20% lower than to the first questionnaire. In order to reduce the 
possibility of selection bias and to maintain statistical power, we decided to include 
women with missing information on smoking (n=6,255), alcohol use (n=6,746) and 
physical activity (n=7,593) in our study sample. These variables were coded 
“missing”.  
 Another possible selection bias may have been introduced by not having 
excluded women who had undergone hysterectomy at study baseline or during 
follow-up. Information on hysterectomy was lacking in HUNT 1. Even if the rate of 
hysterectomies used to be low in Norway 103, the number of women with intact uterus 
and thereby at risk of uterine cancer is lower than the denominator of our estimations. 
It has been suggested that incidence rates of endometrial cancer in women at risk, 
corrected for hysterectomy status, may yield rates up to 29% higher than in the total 
population of women 104. Consequently, the endometrial cancer incidence in women 
at true risk may be underestimated in our studies. There is, however, no evidence of 
a difference in hysterectomy rates dependent on BMI. In HUNT 2 information on 
previous hysterectomy was available, but the estimates of BMI as a risk factor 
remained unchanged after having corrected for hysterectomy status (paper II). 
Hence, we have no reason to believe that lack of exclusion of women having 
undergone hysterectomy has biased our estimates of the association of BMI with 
endometrial cancer risk. However, our predicted future rates of endometrial cancer as 
presented in paper IV may be overestimates since increasing hysterectomy rates in 
Norway have reduced the number of women at risk for uterine cancer. 
Selection in follow-up in our study sample: The HUNT databases were linked to the 
Cancer Registry of Norway and to the Cause of Death Registry at Statistics Norway. 
Hence, study participants could be followed until the date of uterine cancer diagnosis, 
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emigration, death or to the end of follow-up. Women with incident cancer other than 
basal cell carcinoma were also censored at date of diagnosis. 
 In order to avoid biased estimates, the association between exposure and the 
disease in censored individuals should not differ from the population that could be 
studied until the end of follow-up. Obesity, however, is a risk factor for several other 
cancers, such as colon-, kidney-, gallbladder- and postmenopausal breast cancer. 
Therefore, censoring of women with cancer of other organs than the uterus, may 
have led to an underestimation of the impact of BMI on endometrial cancer risk. Any 
cancer treatment during follow-up or prior to inclusion could have had an impact on 
the risk of endometrial carcinoma. However, the direction of the possible bias cased 
by such non differential selection is not easily determined. 
 
5.1.2 The role of information bias 
Information bias result from systematic differences in the way data are obtained and 
may affect both independent and dependent variables. Both systematic differences in 
registration of exposure according to the outcome or in registration of outcome 
according to exposure may result in information bias.  
 
The independent variables: A form of information bias called recall bias occurs, when 
cases may be likely to remember their exposure differently than controls. The 
prospective design of the studies presented here will generally prevent recall bias, 
since information on exposure information was ascertained before the occurrence of 
cancer.  
An inherent assumption of this type of study is that exposure stays constant 
over the observation period. However, body weight and smoking habits may have 
changed during follow-up. Longitudinal data from HUNT 1 and 2 indicate that most 
women (66%) have gained weight between the two surveys 105. There was no 
association of weight change with initial BMI. Thus, we have no reason to assume 
changes in weight during follow-up differ systematically by weight at study induction. 
There is therefore little chance that changes in weight during follow-up have 
introduced systematic errors. Still, the impact of BMI in our study may be 
overestimated if weight gain during follow-up explains part of the association. There 
are to date no prospective studies with successive BMI measurements during follow-
up which could elucidate the relationship between duration of obesity and 
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endometrial cancer risk. Endometrial cancer may also be initiated several years prior 
to the clinically detectable stage. Thus, the importance of constant exposure during 
the follow-up may not be as important as during the period prior to study induction. 
Age at menopause or menopausal status could not be directly obtained from 
the HUNT 1 study. We have therefore chosen the age of 55 years as a proxy for age 
at menopause. Follow-up time was calculated from date of clinical examination until 
endometrial cancer before the age of 55 or until censoring at the age of 55. We 
cannot exclude that some postmenopausal women may have been misclassified as 
pre-/perimenopausal. Unless there is a differential misclassification of age at 
menopause according to BMI, there is little reason to assume that the effect of BMI in 
premenopausal women is biased. To my knowledge, BMI is not established as 
determinant of age at menopause. 
 
The dependent variables: The completeness and validity of the cancer diagnoses 
(topographic codes) in the Cancer Registry is well documented 98. Hence, endpoints 
were ascertained with limited error. It is possible that improved reporting of cancer 
and improved diagnostic efforts have contributed to the increase in endometrial 
cancer incidence over time. An easily performed endometrial sampling method 
introduced in the 1990s may have led to detection of more cases of cancer and also 
to earlier detection of endometrial cancer with a shift towards increased incidence 
among younger women. It is possible that the increased incidence in pre- and 
perimenopausal women could be explained by such a drift and may have influenced 
recent incidence rates (paper IV). 
Women with high BMI tend to suffer from a range of comorbidities (diabetes 
mellitus, hypertension) that require medical treatment. This may increase the 
likelihood of being diagnosed with endometrial cancer since these women are more 
likely to have regular contact with doctors. If this is true, the impact of BMI on 
endometrial cancer may have been overestimated in our studies. It can also be 
argued that obese women die of other diseases before they would have been 
diagnosed with endometrial cancer. Then, the impact of BMI on endometrial cancer 
risk may have been underestimated. 
 In our studies we used the International Classification of Diseases, 7th 
revision, ICD-7, code 172 to identify women diagnosed with uterine cancer. 
Approximately 10% of the cancers registered by this code may, however, not 
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originate from the endometrium (Table I). Assuming that BMI is a risk factor for 
endometrial cancer only and not for other cancers localized in the uterus, the impact 
of BMI on cancer truly originating from the endometrium may be underestimated in 
our study. 
 The Cancer Registry also provided information on the histological subtype of 
endometrial cancer. However, in 1993 the Cancer Registry changed the classification 
system of tumour morphology from MOTNAC to ICD-O-2, also due to the growing 
awareness of type I and type II cancers. As the MOTNAC classification does not 
differentiate type I and type II tumours, we included unspecified adenocarcinoma, 
villoglandular adenocarcinoma, adenocarcinoma with squamous differentiation and 
endometrioid adenocarcinoma (MOTNAC codes 8143, 8144, 8145) in the analyses of 
endometrioid carcinomas in paper III. The remaining 111 (64%) of the endometrioid 
adenocarcinomas in this analysis were diagnosed after 1993, when the classification 
distinctly differentiated between type I, type II and other tumours of the endometrium. 
In total, 74% (n=166) of all endometrial cancers were classified as endometrioid 
adenocarcinomas (type I), which is in concordance with the distribution of histological 
subtypes in the literature 106. Assuming that type II tumours falsely may have been 
classified as type I, the impact of BMI on endometrioid adenocarcinomas is 
underestimated in our study (paper III). However, there is no reason to assume a 
differential misclassification of tumour histology according to BMI, and biased 
estimates are therefore unlikely. A higher accuracy of the histological diagnoses and 
thereby increased validity of our dependant variable could have been achieved by 
pathological review of all uterine cancers included in our studies. This would also 
have enabled us to study type I and type II tumours separately. However, paraffin-
embedded tissue of the women diagnosed with uterine cancer in the HUNT study 
was not available to us. 
 
5.1.3 The role of confounding 
Confounding is the systematic error generated when another factor that is associated 
with the disease under study, also is related to the exposure variable. Adequate 
adjustment for potential confounders depends on two conditions that must be 
satisfied: (i) the association with the disease is known and (ii) the identified or 
suspected confounders can be measured with adequate validity and accuracy. 
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Early menarche, nulliparity and hormone replacement therapy (HRT) are positively 
associated with the risk of endometrial cancer, whereas use of combined oral 
contraceptives (COCs) reduces the risk. Information on reproductive factors, the use 
of COCs and HRT could not be obtained from HUNT 1 and was missing in a high 
proportion of women in HUNT 2. High BMI is associated with infertility due to chronic 
anovulation, and a higher proportion of nulliparous women may therefore be 
observed in higher BMI categories. As nulliparity also is a risk factor for endometrial 
cancer, lack of controlling for this confounder may have led to an overestimation of 
the impact of BMI. One may also argue that BMI increases with parity which is 
negatively associated with risk. If this is true, our estimates may be an 
underestimation of the true association with BMI. However, information on parity was 
included in paper II but did not alter the reported associations between BMI or blood 
lipids and endometrial cancer risk. 
 Use of HRT was generally uncommon among Norwegian women. In the late 
1980s less than 6% of postmenopausal women used HRT 107, but the use increased 
rapidly in the 1990s, reaching a peak of about 35% towards the end of the decade 108 
with predominantly combined estrogen-progesterone preparations. A minor increase 
in risk compared to unopposed estrogen therapy has also been reported for the 
combined treatment 19;20. There is no evidence that the use of HRT differs across 
BMI categories, and it is difficult to determine how inclusion of this confounder may 
have influenced our results. 
 The observed results may also be attributable to other, unmeasured variables 
not yet known to be related to the risk of endometrial cancer. The observed trends of 
endometrial cancer incidence over the last five decades presented in paper IV are 
complex and may not exclusively be explained by changes in key risk factors such as 
reproductive behaviour, use of HRT or combined oral contraception and the 
increased prevalence of obesity. 
 
5.1.4 Statistical power 
Another source of error can arise from failing to reject the null hypothesis given that 
the alternative hypothesis is actually true (type II error). A type II error is frequently due 
to sample sizes being too small. In our thesis we had limited statistical power to study 
different subgroups of i) exposure and ii) endometrial cancer. 
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Paper I: We conducted separate analyses for women at risk of endometrial cancer 
before and after the age of 55. Only 52 women developed cancer before 55 years of 
age, and of those very few (n=9) were obese (BMI 30). Thus, estimates of the impact 
of BMI in younger women were calculated with wide confidence intervals and limited 
precision in higher categories of BMI.  
Paper III: The majority of endometrial carcinomas are classified as endometrioid 
adenocarcinomas (type I), and we were not able to conduct separate analyses in 
women with type II tumours with sufficient statistical power. We therefore chose to 
study the following subgroups: All uterine cancers, all endometrial cancers and all 
endometrioid adenocarcinomas. We also assessed the association of BMI and the 
risk of uterine cancers other than endometrioid adenocarcinomas. The results show 
an increased risk associated with BMI of 35 or higher but no associations for the 
other BMI categories. Both analyses suggest a stronger association with 
endometrioid adenocarcinoma than for uterine cancers as a whole. 
Paper IV: We studied incidence trends of endometrial cancer in pre-/peri- and 
postmenopausal women separately. We suggest that the increasing BMI in Norwegian 
women since the mid-1980s may in part explain the increase in rates in 
postmenopausal women in recent years and the shift towards increased incidence in 
younger women. However, the underlying random variation due to small numbers 
limits the statistical power of our estimates in the younger age group. 
 
5.2 Obesity and endometrial cancer – Proposed mechanisms 
We found a strong positive and linear association of BMI with the risk of endometrial 
cancer. This association may be particularly strong in endometrioid 
adenocarcinomas. We also report a positive association of serum triglycerides with 
endometrial cancer risk. Adjustment for BMI partly attenuated the association, 
suggesting that some of the effect may be mediated through obesity. The strongest 
support for a link between obesity and endometrial cancer risk involves the metabolic 
and endocrine activity of adipose tissue, and the alterations that they induce in the 
production of peptide and steroid hormones.  
 An underlying assumption of our study is that body mass is an adequate 
measurement of adiposity. There are two types of adipose tissue, subcutaneous and 
visceral. Subcutaneous tissue is largely defined as fat tissue between skin and 
muscle, whereas visceral adipose tissue is found within the main cavities of the body, 
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primarily in the abdominal cavity. Abdominal visceral adipocytes are metabolically 
more active than abdominal subcutaneous adipocytes, as they have high lipolytic 
activity and release large amounts of free fatty acids 109. Consequently, the ideal 
measurement of adiposity would consider both the amount and the site of deposition 
of the adipose tissue. Many methods of estimating total body fat mass have been 
developed, but they are generally too costly and complex to be used to estimate 
adiposity in general populations or large epidemiological studies. Thus, estimations of 
overweight and obesity have historically been based on anthropometric measures 
such as BMI. A recent study evaluated if DEXA (dual-energy X-ray absorptiometry) is 
a more precise measure of adiposity than BMI and if those two measurements can 
predict sex hormone levels in postmenopausal women 110. They showed that 
measurement of adiposity just by using BMI was sufficient to accurately characterize 
sex hormone levels. 
 A number of biomarkers associated with both obesity and endometrial cancer 
may play a role in the neoplastic transformation of endometrial cells, and the main 
endocrine pathways are elucidated in the following. 
 
Endogenous sex steroids: The predominant theory describing the relationship 
between endogenous steroid hormones and endometrial cancer risk is known as the 
unopposed estrogen hypothesis. This theory originated from two important 
observations: (i) Endometrial proliferation rates are increased during the follicular 
phase, when progestin levels are low, whereas E2 levels are at normal 
premenopausal concentrations 111. (ii) Continuous exposure to exogenous estrogen 
without progestin resulted in increased endometrial cancer risk 112. Adiposity 
influences the synthesis and bioavailability of endogenous sex steroids through at 
least three mechanisms (Figure VIII). First, adipose tissue is an important source of 
endogenous estrogen due to the conversion of androstendione to estrone and the 
aromatization of androgen to estradiol 113. Second, the mitogenic effect of estrogen in 
obese women is assumed not to be counterbalanced by progesterone due to chronic 
anovulation and thereby strongly reduced progesterone synthesis. Progesterone 
diminishes estrogenic action in the endometrium by stimulating the local synthesis of 
17-hydroxysteroid dehydrogenase and estrogen sulfo-transferase 114. These 
enzymes favour the conversion of E2 into the less potent E1, and into estrogen 
sulfate. Both are rapidly excreted from the cells and from the body. Furthermore, 
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progesterone provides the key stimulus for endometrial gene expression and 
synthesis of IGFBP-1 (insulin-like growth factor binding protein 1), which inhibits 
IGF-1 (insulin-like growth factor 1) action in endometrial tissue 115;116. IGF-1 is a 
peptide hormone that has a molecular structure very similar to that of insulin and 
regulates cellular proliferation in response to available energy and nutrients from diet 
and body reserves. It has been argued that low progesterone, rather than increased 
estrogen is the predominant determinant of endometrial cancer in premenopausal 
women and that the increased risk is only related to estrogen when estrogen 
concentrations are comparatively low, as found in postmenopausal women. In 
postmenopausal women, estrogen derived from peripheral adipose tissue is the 
primary source of endogenous E2, and the rate of production is related to the size of 
the adipose depots 117. It can be argued that only in those women, with comparably 
low estrogen concentration, endometrial cancer risk is directly related to circulating 
estrogen. Finally, adipose cells increase circulating levels of insulin and increase 
IGF-1 bioactivity. This results in reduced hepatic synthesis and blood levels of SHBG 
(sex-hormone binding globulin), a plasmatic binding protein with specific affinity for 
estradiol and testosterone. Adiposity-related decreases in SHBG levels generally 
increase the fraction of bioavailable estradiol. Our results may support the hypothesis 
of different mechanisms in the development of endometrial cancer in different age 
groups leading to a threshold effect of BMI in younger, premenopausal women. Still, 
there are only few cases (n=52) in this age group, and data from this study 
population are insufficient to draw a definite conclusion. 
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Figure VIII: Obesity, hormones and endometrial cancer 117 
 
Insulin, glucose, IGF-1 and SHGB: We found a positive association of diabetes with 
endometrial cancer risk after adjustment for potentially confounding factors. We also 
report a positive association of serum triglycerides with endometrial cancer risk. 
Adjustment for BMI partly attenuated the association, suggesting that some of the 
effect may be mediated through obesity. Excess weight, increased plasma 
triglyceride levels and low levels of physical activity can additionally raise circulating 
insulin levels. A number of mechanisms are thought to play a role in linking elevated 
insulin to endometrial cancer development, including growth enhancing properties of 
insulin, increased levels of IGF-1 receptors in endometrial cancer tissue 118;119 and 
suppressed gene expression of endometrial IGFBP-1 leading to increased biological 
activity of IGF-1 120;121 (Figure IX). In vitro studies have clearly established that both 
insulin and IGF-1 act as growth factors that can promote cell proliferation and inhibit 
apoptosis 122. Insulin also reduces hepatic synthesis and plasma levels of SHBG 
increasing bioavailable E2 unbound to SHBG. In vitro studies have demonstrated that 
insulin also up-regulates the secretion and mRNA expression of VEGF, a potent 
angiogenic factor, that may contribute to endometrial carcinogenesis 123;124. 
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Figure IX: Effect of obesity on insulin and growth factor production 27 
 
Adiponectin: Adiponectin is a peptide hormone secreted in large amounts by 
adipocytes with reduced circulating levels in conditions related to insulin resistance, 
such as visceral obesity and type 2 diabetes 125. Three relatively small case-control 
studies 126-128 and one larger prospective case-control study within the EPIC 
(European Prospective Investigation into Cancer and Nutrition) cohort study 129 
showed adiponectin levels to be negatively associated with the risk of endometrial 
cancer, largely independent of other obesity related factors like IGF-1, IGF-2, IGFBP, 
leptin and BMI. Plasma adiponectin concentrations have been shown to be more 
closely related to insulin resistance than to the degree of obesity 130. One major 
metabolic pathway through which adiponectin could influence endometrial cancer risk 
is by decreasing blood insulin and glucose levels as it increases fatty acid oxidation 
in the muscle, decreases hepatic glucose production and increases insulin sensitivity 
of peripheral tissue. Adiponectin may have strong anti-inflammatory activity and could 
thereby potentially counteract the proinflammatory and neoplastic effects of TNF- 
(tumour necrosis factor alpha), IL-6 (interleukin 6) and C-reactive protein. These 
cytokines have an impact on endometrial carcinogenesis by increasing nuclear 
factor-B, prostaglandin E2 levels and cyclooxygenase-2 expression. TNF- can also 
stimulate estrogen biosynthesis and angiogenesis 131. 
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Leptin: Leptin is another protein secreted by white adipose tissue. This hormone is 
strongly associated with obesity but there is to date only one small case-control study 
on the association of plasma leptin levels and the risk of endometrial cancer 132. 
Leptin was unrelated to the risk of endometrial cancer when adjusted for BMI. In vitro 
studies, however, suggest that leptin may promote a proliferative response and 
invasiveness in human endometrial cancer cells. A recent study on six endometrial 
cancer cell lines identified several pathways (JAK2/STAT3, MAPK/ERK, PI3K/AKT 
and COX-2 signalling) that seemed to be implicated in the cell proliferative effect of 
leptin 133. 
 
Peroxisome proliferator-activated receptors (PPARs): Besides a strong increase in 
risk of endometrial cancer in women with high body mass, we report a positive 
association of triglycerides with endometrial cancer risk. This association persisted 
after adjustment for the other serum lipids but was partly attenuated after adjustment 
for BMI. This suggests that some, but not all of the effect related to triglycerides may 
be mediated by body mass. The challenge is to understand how obesity and 
triglycerides influence the risk of endometrial cancer, either through their combined 
relation or as independent factors. Certain nuclear receptors can modulate both 
cellular lipid metabolism and tumorigenesis 134. For instance, peroxisome proliferator-
activated receptors (PPAR) can mediate lipid homeostasis and adipogenesis 135, as 
well as cancer cell growth 136;137. Three subtypes, PPAR, / and 	, have been 
identified. Activation of PPAR by fibrates leads to lower triglyceride levels and 
appears to be an effective treatment of dyslipidemia 138;139. In endometrial cancer, 
PPAR seems to be up-regulated, and it has been shown that fenofibrate exhibits 
antiproliferative effects on endometrial cancer cells in vitro via inhibition of G1/S 
phase progression 140. Cyclin D1 is known to be upregulated in endometrial 
cancer 141;142, and administration of PPAR agonists led to downregulation of cyclin 
D1 and upregulation of p21. In conclusion, there is growing evidence of direct action 
of this lipid-lowering agent on pathways known to be relevant to endometrial 
carcinogenesis. 
 A number of investigators have shown PPAR	 expression in a variety of 
tumour cells, and Ota et al. 143 reported lower PPAR	 expression in endometrial 
cancer tissue than in normal tissue. PPAR	 expression was negatively correlated 
with BMI suggesting that genetic or environmental factors causing obesity might 
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interact with the PPAR gene. In addition, the PPAR	 agonist 15d-PGJ2 inhibited 
endometrial cell proliferation and raised plasma adiponectin levels making synthetic 
PPAR	 ligands potential drug candidates for both prevention and endocrine 
treatment of endometrial carcinoma 72;140. 
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6. PUBLIC HEALTH IMPLICATIONS 
 
Our studies imply that even a slight increase in BMI in the population will lead to an 
increase in endometrial cancer incidence. The incidence increase among 
premenopausal women during the last 15 years may be a direct effect of the marked 
increase in BMI in young women. We present two scenarios in this thesis of the future 
burden of endometrial cancer. The conservative scenario assumes decreasing 
exposure to underlying risk factors over time. The less optimistic scenario with an 
estimated 95% increase in the number of new cases by 2025 (1257 new cases) 
implies unchanged trends in exposure to underlying risk factors and that cumulative 
exposure to risk factors like high BMI causes a linear increase in risk. 
 Our findings may have important public health implications. There are to date 
no reliable predictions of the development of BMI in Norway, but an increasing and 
substantial proportion of adolescents are overweight or obese 144. The proportion of 
endometrial cancers due to obesity has been estimated to about 40-60% 27;145, and by 
preventing obesity, a considerable proportion of endometrial cancer cases may be 
avoided. 
 Increased physical activity, healthy food choices and weight maintenance may 
contribute to prevent obesity and thereby endometrial cancer, even if an independent 
protective effect on endometrial cancer have yet not been observed 94. Observational 
cohort studies have shown that bariatric surgery results in profound weight loss and 
reduced cancer risk 146. 
 One of the barriers to endometrial cancer prevention, however, is the lack of 
public awareness of the association between endometrial cancer and obesity. A 
survey study of 1,545 women in the Houston community in the US explored if women 
in the general population were aware of the relationship between excess weight and 
cancer risk 147. 24% of the women were overweight and 45% were obese. 58% of all 
study participants were not aware that obesity increased the risk for endometrial 
cancer. There was no difference in knowledge associated with any of the demographic 
characteristics studied (age, racial/ethnic group, level of education, household income 
and access to insurance). In a similar study in Germany, 96% of participants felt they 
would benefit from more information regarding risk factors for endometrial cancer 148. 
The development of public educational programs and interventional strategies, both at 
an individual and community level, are likely to be needed to maximize preventive 
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efforts. Those may be similar to the tobacco cessation efforts where benefits for lung 
and heart conditions were observed much earlier than a decrease in cancer 
rates 149;150. The tobacco control efforts also taught us that policy and environmental 
changes are crucial to achieving changes in individual behaviour. Efforts to address 
the obesity epidemic will require the action of the government, industries, 
communities, schools, primary health care providers, specialists and the individual. 
Efforts should aim at increasing the awareness of the problem and its association with 
chronic illnesses and cancer, at changing attitudes regarding healthy nutrition and 
increased physical activity, helping individuals change their behaviour and introducing 
environment supports for behaviour change. 
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7. FUTURE PERSPECTIVES 
 
Our studies encourage more detailed research on the association between body mass 
and endometrial cancer. Further epidemiological studies with sufficient power are 
needed to elucidate the impact of BMI in premenopausal women. 
 Knowledge on how the impact of risk factors differs by histology is still scarce. 
Future studies based on cases with accurate histological diagnoses may assess how 
obesity is related to different subtypes of uterine cancer. Incidence trends of uterine 
cancer according to histological subtype may also increase our knowledge of the 
nature of the endometrial cancer epidemic and elucidate if risk factors are differentially 
associated with histological subtypes. Analyses in countries with a similar BMI 
development like Norway would add to our suggestion that the increase in endometrial 
cancer incidence may be due to the marked increase in BMI in the population. They 
may also help to elucidate the role of improved diagnostic in the development of 
endometrial cancer incidence. Studies with successive BMI measurements during 
follow-up may help to understand the impact of cumulative exposure to 
overweight/obesity and their effect according to age. 
 It also remains to be determined whether serum triglycerides play an 
independent role in relation to endometrial cancer risk. Other prospective studies are 
needed to better understand the association of blood lipids and endometrial cancer. 
 Future research to understand the biological role of obesity in cancer 
development is needed. At present, the biological mechanisms that link overweight 
and obesity to endometrial cancer are insufficiently understood. Obesity-associated 
dysregulation of adipokines is likely to contribute not only to tumorigenesis and 
tumour progression, but also to the metastatic potential. Adipokines may cause 
changes in hormone metabolism and also interfere with the regulation of the 
inflammatory and immune response. It has also been hypothesized that adipokines 
influence vascular and stromal interactions and angiogenesis. Additional studies of 
these factors will add to our understanding of adipose tissue as an endocrine and 
regulatory organ. 
 Among postmenopausal women only, risk of endometrial cancer was directly 
related to levels of estrone and bioavailable estradiol 151. Little is known about the 
impact of obesity-related increase in endogenous sex-steroid levels and endometrial 
cancer risk among premenopausal women. Studies should also examine the 
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relationship between blood levels of factors related to insulin resistance such as 
C-peptide, IGF-binding proteins and IGF-1 and endometrial cancer risk. 
 Knowledge on the molecular pathways linking obesity, insulin resistance, 
diabetes mellitus and endometrial cancer may allow for the development of targeted 
endocrine therapy. The administration of metformin, an antidiabetic drug, has been 
shown to decrease cancer risk in type-2 diabetes in one large observational study 152, 
but no effect was detected in another population-based cohort study 153. Clinical 
studies are needed to evaluate the utility of metformin in the treatment of cancer 
patients. Synthetic PPAR	 ligands (thiazolidinediones, including troglitazone and 
rosiglitazone) may be another treatment option. Various in vitro studies have 
demonstrated their antiproliferative activity for a wide variety of neoplastic cells 154. 
Still, little is known about PPAR	 expression in endometrial carcinoma, and the 
effects of PPAR	 agonists in these patients are largely unknown. 
 There are to date few clinical studies that have assessed the prognostic 
impact of BMI. Two large cohort studies showed that women with high body mass 
index had a significant higher risk of death from any cancer 34;155. The highest relative 
risk was observed for death from uterine cancer (relative risk 6.25, 95% CI: 3.75-
10.42 for women with BMI 40). These results may be due to obesity-related 
differences in the diagnosis or treatment of cancer, as well as true biological effects 
of obesity on survival. A report of the Gynecologic Oncology Group found BMI not to 
be related to the risk of endometrial cancer recurrence but to a decreased overall 
survival. This may be explained as death caused by comorbidities related to obesity 
and not cancer progression 156. Another report found obesity related to favourable 
histology, lower grade and earlier stage disease. Obesity was also associated with 
increased time-to-recurrence rates and survival 157;158. In order to evaluate the 
prognostic impact of BMI it may be instructive to study the association of BMI with 
other pathologic and molecular features. Recently, inactivation of PTEN/p27kip1 was 
observed to be a specific feature of endometrial cancer in obese women, suggesting 
that BMI may be related to a certain phenotype of endometrial cancer 159. 
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8. CONCLUSIONS 
 
I. In this study there was a linear and strong positive association of BMI with the risk 
of endometrial cancer. The linear association between BMI and endometrial cancer 
implies that even a slight increase in population body mass will lead to an increase in 
endometrial cancer incidence. 
 
II. Women with diabetes had three-fold higher risk of endometrial cancer. 
 
III. This study suggests an inverse association of endometrial cancer with smoking. 
 
IV. The results of this study suggest a positive association of serum triglycerides with 
endometrial cancer risk. Adjustment for BMI partly attenuated the association, 
suggesting that some of the effect may be mediated through obesity. There were no 
associations (positive or negative) between total serum cholesterol, HDL cholesterol, 
non-HDL cholesterol and LDL cholesterol and the risk of endometrial cancer. 
 
V. Our results suggest a positive association of BMI with all subtypes of uterine 
cancer, but the association may be strongest for endometrioid adenocarcinomas. 
 
VI. This study provides evidence of a consistent increase in the incidence of 
endometrial cancer during the last 50 years. The increase has been more 
pronounced in postmenopausal women, but in the last decade the same trend has 
been observed in pre- and perimenopausal women. Our long-term predictions imply 
that the burden of endometrial cancer will continue to increase in the forthcoming 
decades. 
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This study provides evidence of a consistent increase in the incidence of endometrial 
cancer during the last 50 years. We suggest that the obesity epidemic may in part 
explain the increasing rates in postmenopausal women, but in recent years, also in 
younger women. Based on the future predictions endometrial cancer rates will 
dramatically increase unless effective preventive strategies are implemented. 
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ABSTRACT 
Endometrial cancer is the most common cancer of the female genital tract in Western 
countries. Monitoring the incidence is important for health care planning and the 
identification of risk factors.  
We present an age-period-cohort analysis of incidence trends of endometrial cancer 
in Norway from 1953 to 2007 and compare the incidence trends with those in three 
other Nordic countries. Based on the observed trends we have predicted endometrial 
cancer rates in Norway in 2015 and 2025.   
In women at postmenopausal age (55 years), the annual incidence increase was 
2.1% (95% CI: 0.9%, 3.4%) from 1988 to 1997 and 1.7% (95% CI: 0.6%, 2.8%) from 
1998 to 2007. In younger women, there was an annual reduction of 0.6% (95% CI: -
2.3%, 2.2%) from 1988 to 1997, followed by an annual increase of 1.7% (95% CI: -
0.4%, 3.9%) from 1998 to 2007. The secular changes are likely to reflect both cohort 
and period effects. Our prediction estimates by 2025 suggest an incidence increase 
in the range of 50% to 100%, relative to the observed incidence in 2005.  
There has been a strong and consistent incidence increase in endometrial cancer in 
the Nordic countries over the last 50 years. The increase has been most pronounced 
in postmenopausal women, but in the last decade, rates have increased also in 
women younger than 55 years. The prediction for the next 20 years suggests that 
endometrial cancer rates will dramatically increase unless effective preventive 
strategies are implemented. 
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INTRODUCTION 
Endometrial cancer is the most common cancer of the female genital tract in many 
Western countries and some of the highest incidence rates are observed in European 
populations (1). Temporal incidence trends appear to differ by menopausal status, 
and in Norway, as in other Nordic countries, the increasing incidence of 
postmenopausal endometrial cancer contrasts with the declining rates observed in 
premenopausal women (2).  
 Monitoring the incidence is important for health care planning purposes and for 
the identification of risk factors. The planning of health services is an integral 
component of cancer control programmes (3), and prediction of future rates is 
therefore of great interest to society. 
 The etiology of endometrial cancer is unknown, but the main hypothesis has 
emphasized exposure to high levels of circulating estrogens in conjunction with 
inadequate levels of progesterone (4). The use of unopposed estrogen replacement 
therapy in postmenopausal women is associated with increased risk (5), whereas use 
of combined oral contraceptives (COCs) confers a degree of protection (6). Other risk 
increasing factors include nulliparity (7-10), obesity and diabetes (11-16), while 
cigarette smoking (17) and delayed childbearing (18) may be inversely associated 
with endometrial cancer risk.   
 In this study we present an age-period-cohort analysis of the observed 
incidence trends of endometrial cancer in Norway from 1953 to 2007, comparing 
these trends with those in three other Nordic countries (Sweden, Denmark and 
Finland). Based on the Norwegian trends, we provide two model-based scenarios of 
the future burden of endometrial cancer in Norway, predicting the number of new 
cases and incidence rates in 2015 and 2025.  
 
MATERIAL AND METHODS 
Incidence data. Incident cases of corpus uterine cancer (ICD-10 C54) were extracted 
from the Cancer Registry of Norway for the years 1953-2007, with corresponding 
person-years at risk within age groups obtained from the population data available at 
Statistics Norway (http://www.ssb.no). The Norwegian cancer registration system is in 
accordance with international standards and has an estimated completeness of 
around 98% overall, and above 99% for cancers of the corpus uteri for the years 2001-
2005 (19). A high level of ascertainment is considered the result of mandatory 
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reporting from all hospitals, laboratories and general practitioners in Norway, in 
combination with the routine trace-back systems in place (19). 
 The vast majority of cancers of the uterine corpus are endometrial 
adenocarcinomas, and hereafter we refer to the disease as endometrial cancer. 
 
Statistical analysis. To assess the time trends, the age distribution of the world 
standard population (20;21) was used to calculate age- standardized incidence rates 
per 100 000 by five-year time periods (1953-57, 1958-62,..., 2003-07). Truncated 
age-standardized rates and cumulative risk for the age groups 0-54 and 55-79 years 
were also calculated, with lifetime risk estimated for all ages up until 80, on assuming 
an absence of competing causes of death. A comparison of five-year moving 
averages of the age-standardized rates in Denmark, Finland and Sweden were 
extracted from the NORDCAN website (22) to serve as a comparison.  
  Restricting the age range to 35 to 79 years, 10-year synthetic cohorts were 
defined for women born in 1874-83, 1879-98,..., 1964-73 on subtracting the 
midpoints of five-year age groups from the corresponding midpoints of five-year 
aggregates of calendar time. The observed trends were presented as rates versus 
birth cohort by age, and rates versus calendar period by age, with quasi-parallelism 
of the age-specific curves on either time scale, an indication of their respective 
influence on the temporal pattern.  
 Cohort effects are established if changes in rates are seen in successive birth 
cohorts. They commonly arise through a changing prevalence and distribution of one 
or more key risk factors for the disease under study. Period effects are characterized 
by an immediate or fixed-delayed change in the incidence for all age groups, and 
may therefore act as surrogate measures of exposures that quickly change rates 
across all age groups. They may include changes in classification criteria, the 
availability of new diagnostic tests, or specific interventions that affect rates in all 
studied age groups.  
To formally assess the importance of the non-linear effects of period and 
cohort and the goodness of fit of sub-models, a standard analysis of deviance of 
nested age-period-cohort (APC) models was performed, treating age, period and 
cohort as factors (23;24).  
 The APC model cannot estimate the individual linear components of the age, 
period, and cohort effects due to their linear dependence (25).Thus, we present two 
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unique sets of estimates from the full APC model, one with an allocation of the net 
drift (the identifiable sum of the period and cohort slopes) to birth cohort, and another 
assigned to calendar period. By setting the linear component of the period (cohort) 
effects to zero, we present the cohort (period) effects, hypothesizing that they 
predominate the underlying trends. The method still enables presentation of the non-
linear period (cohort) effects in each set of estimates. The model analysis was 
performed using the APC functions available in the library Epi (version 1.0.8) in R 
(26), and specifically the apc.fit command. Both period and cohort effects are 
presented as rate ratios, with the age-specific rates relative to the corresponding 
median cohort or period. Stata 10 was used for data management and the plotting of 
the observed trends (27). 
 
Future predictions for 2015 and 2025 
In order to predict incidence trends for four five-year periods (2008-2027), APC models 
were fitted that allowed two different scenarios of the disease burden by extrapolating 
the four most recently observed five-year periods (1988-2007): Scenario A involved 
use of (i) a power function to level off the growth, thus avoiding the overestimation of 
cases associated with the method based on the multiplicative model, and (ii) projection 
of the recent linear trend based on the last 10 years (1998-2007) of observed data, 
attenuated by 25%, 50% and 75% in the second (2013-17), third (2018-22) and fourth 
(2023-27) prediction period, respectively. In a previous comparison of 15 different 
prediction methods, it was shown that the underlying model provided among the best 
estimates of future cancer burden (28). The predicted rates and numbers based on 
scenario A represent a conservative future pattern. An alternative scenario B used the 
same specifications as in (i) above, but assumed no attenuation of the linear trend (a 
constant drift) in future periods. For both scenarios we present the numbers of new 
cases and incidence rates for the midpoints of the second and fourth period, in 2015 
and 2025, respectively. 
 The numbers of new cases were predicted by multiplying the projected 
incidence rates by official national population forecasts for future years obtained from 
Statistics Norway for 2015 and 2025 by the 5-year age group, based on the ”medium 
variant” and assumptions on future fertility, life expectancy, internal mobility and net 
immigration. Differences predicted numbers of new cases, relative to those observed 
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around 2005 are presented on partitioning the changes into those due to 
demographics (population aging and growth) and those due to changing risk (rates). 
 
RESULTS 
Trends by calendar period in Norway and the Nordic countries 
Endometrial cancer rates in women younger than 55 years tend to be higher in 
Norway than in other Nordic countries, but at older ages, rates in Norway, Sweden and 
Finland have converged during the last two decades (Figure 1). The cumulative risk 
(prior to 80 years) has increased over time and is estimated to approximately 2.5% for 
women diagnosed between 2003 and 2007. This estimate suggests that one in 40 
women will be diagnosed with endometrial cancer during their lifetime.  
 Between 1988 and 2007, the annual incidence increase in endometrial cancer 
was 1.7 % among Norwegian women under 80 years of age (Table 1), however, the 
temporal increase differed by age group. In women 55-79 years, the annual increase 
was roughly the same during the two decades; 2.1% (95% CI: 0.9%, 3.4%) from 1988 
to 1997 and 1.7% (95% CI: 0.6%, 2.8%) from 1998 to 2007. In women younger than 
55 years, there was an annual reduction of 0.6% (95% CI: -2.3%, 2.2%) from 1988 to 
1997, followed by an annual increase of 1.7% (95% CI: -0.4%, 3.9%) from 1998 to 
2007. Estimated as cumulative incidence, about one in 250 women was diagnosed 
with endometrial cancer in Norway before the age of 55 years during 2003-7.  
 A similar decline among women at premenopausal age has taken place in the 
other Nordic countries, beginning in the early 1980s (Figure 1). In Sweden, the decline 
started before the three other countries, and has also been stronger. In Finland, there 
was first a decreasing incidence followed by increasing rates in women younger than 
55 years. Denmark represents an exception to the uniform patterns of increased 
postmenopausal incidence since around 1985. The rates in women 55 years or older 
declined during the 1980s and early 1990s, however, there has been an increase in 
incidence in Denmark from the late 1990s.  
  
Age-period-cohort analyses of the incidence 1953-2007 in Norway 
Age-specific rates by birth cohort and period of diagnosis are complex and difficult to 
interpret (Figure 2). However, it is instructive to partition the rates into pre- and 
postmenopausal age groups. There was a decline in incidence in Norwegian women 
younger than 55 years both by calendar period and by cohort until 1998, followed by 
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an incidence increase. In women 55 years and older, the rates have consistently 
increased among successive birth cohorts from the late 19th century and thereafter, 
and in consecutive periods of diagnoses from the early 1960s. 
  The full APC model was required in order to yield an adequate fit to the data 
(deviance = 26.6 on 27 degrees of freedom) (Table 2). All effects in the tabulated 
models were significant with the exception of non-linear period effects over and above 
the drift, and on grounds of parsimony, the APC model can be considered the best-
fitting model. Figure 3 presents the modeled trends by age, period and birth cohort 
based on the APC model and two parameterizations (see Methods). Whether we fix 
the linear trend for either period or cohort to zero, increasing rate ratios are observed 
by birth cohort in generations born from around 1880 through to 1925. In generations 
born from 1925 to 1945 the rates are reasonably stable, while for post-war cohorts, 
either parameterization indicates a decline in endometrial cancer rates among 
successive generations born after 1945. Assuming that the underlying linear trend is 
due to calendar period, the analysis of the period effects suggests that rates are 
uniformly increasing throughout the study period, with the observation of a possible 
acceleration in rates since around 1998. 
 
Predicted incidence in 2015 and 2025 
We present observed (1988-2007) and predicted (2008-2027) trends in age-adjusted 
rates in Figure 4. Rates in Norway are estimated to peak around 2020, and 
subsequently decline, assuming a future attenuation in trends (scenario A). With the 
constant drift (scenario B), rates would continue to increase almost linearly up to the 
mid-2020s. Table 3 shows the mean number of cases predicted in 2015 and 2025 by 
age on the basis of the two scenarios compared with the mean number observed in 
2005. The differences are partitioned according to changing risk (rates) and 
demographic changes (population ageing and growth). On the basis of the more 
conservative scenario A, we predict around 873 new cases in 2015, which 
corresponds to an additional 200 diagnoses on top of the 650 cases observed in 
2005, representing a 35% increase in endometrial cancer incidence. Changes in 
underlying risk (18 %) and population aging (17%) contribute almost equally. 
According to scenario A, there will be around 1016 new cases annually circa 2025; or 
57% more cases than in 2005, with about one-third of the increase due to the ageing 
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of the population. By 2025 there will be a larger proportion (22%) of women 
diagnosed with the disease at the age of 80 or older.  
 Applying scenario B, assuming the recent linear increases in the past will continue in 
the future, we predict a doubling of the number of new cases by 2025, corresponding 
to 1257 new cases. The proportion of cases diagnosed at 80 years or older in 2025 is 
estimated to 21% (compared to 18% in 2005). The shift towards more cases at older 
ages is not only related to the ageing of the population, but also to a relatively higher 
mean annual increase in incidence (of about 4% per annum) is observed from 1998 to 
2007 in women 80 years and older (data nor shown).   
 
DISCUSSION 
The age-specific incidence trends of endometrial cancer in Norway from 1953 through 
2007 reveal interesting patterns that may be useful in generating hypotheses that are 
relevant for primary prevention. In women at postmenopausal age (55 years or older), 
there was a general increase in incidence over the entire period, but in younger 
women, patterns were not consistent. In women younger than 55 years, there was a 
general incidence increase until around 1980 that was followed by a decline until 1998, 
after which the rates again have increased until 2007.  
 Despite the high validity of the information recorded by the Norwegian Cancer 
Registry and the well defined Norwegian population, it is possible that increased 
reporting and improved diagnostic efforts have contributed to the increase in 
endometrial cancer incidence over time. An easily performed endometrial sampling 
method introduced in the 1990s may have led to earlier detection of endometrial 
cancer and thereby to a shift towards increased incidence among younger women. It is 
possible that the increased incidence in pre- and perimenopausal women could be 
explained by such a drift. However, it may also be explained by the underlying random 
variation due to small numbers that limit the statistical power of our estimates in this 
age group.  
 The lack of adjustment for the rate of hysterectomies in the population is a 
weakness of this study. Since all women are included in the denominator of our 
estimations – as opposed to including only women with the uterus in place – the true 
risk of endometrial cancer incidence may be underestimated in this population. While 
the rate of hysterectomies has been historically low in Norway, there was a rapid 
increase in the 1990s. Recent estimates suggest that about 12% of Norwegian women 
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will have a hysterectomy performed during their lifetime (29). It has been estimated 
that the incidence of endometrial cancer, adjusted for the prevalence of hysterectomy, 
may yield 30% higher rates than the crude rates without adjustment (30). However, the 
predicted future rates could be an overestimate given that increasing hysterectomy 
rates will reduce the number of women at risk of developing endometrial cancer.
 Another limitation may be the calculation of synthetic birth cohorts based on 
period and age. This creates a linear dependency between the time components and a 
non-identifiability of the linear slopes for age, period and cohort. We were, however, 
able to report the estimates of drift, the sum of the period and cohort slopes, and we 
provide solutions based on an allocation of drift to either period or cohort. This dual 
presentation was considered necessary given the complexity of the trends and the 
inability to estimate the extent to which changes in key risk factors, including 
reproductive patterns, the use of hormone replacement therapy (HRT), use of oral 
contraceptives, and obesity, could have resulted in cohort or period-related linear 
changes. A change in use of oral contraceptives and HRT may affect highly specific 
age groups and time periods, whereas obesity may affect rates in women across all 
age groups over a fixed recent period.  
  The consistent increase in incidence observed in the youngest cohorts is most 
likely due to changes in reproductive factors, including earlier age at menarche and 
lower parity, that are associated with increased risk for endometrial cancer (7-9;18;31). 
Thus, the lowest risk in Norway was observed in the 1890-94 birth cohort. It has 
previously been estimated that about 27% of the increase in cumulative age-adjusted 
incidence from 1955 to 1984 may be attributed to changes in childbearing patterns 
(32). Birth rates have stabilized at around 1.8 during the last 30 years 
(http://www.ssb.no), and maternal age at first birth has gradually increased during the 
last 40 years. However, studies of the impact of age at first or last birth on endometrial 
cancer risk have shown conflicting results (7;9;10;18) and therefore, we do not know 
whether delayed childbearing has contributed to the increase in incidence.  
 Menopausal treatment using estrogens unopposed by progesterone increases 
the risk of endometrial cancer in a dose-risk manner (5), and combined regimens of 
estrogen and progesterone were introduced to prevent this side effect. Nevertheless, 
small increases in risk have been reported also for the combined treatment (33;34) 
and this may account for the increasing rates observed in postmenopausal women 
born after 1940. In the late 1980s less than 6% of postmenopausal Norwegian women 
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used HRT (35), but the use increased rapidly in the 1990s, and reached a peak of 
about 35% towards the end of the decade (36). At that time, the sale was dominated 
by combined estrogen-progesterone preparations. Since then, sales of HRT have 
decreased by more than 50% (37). It seems plausible that the recent decline could 
have attenuated the incidence increase and it is possible that the modest incidence 
reduction in the age group 55-59 years could reflect such an attenuation. Increased 
prevalence of other risk factors, including obesity and diabetes type 2, may have 
contributed to the persisting incidence increase in postmenopausal women.  
  It is well established that the use of combined oral contraceptives (COCs) 
protects against endometrial cancer later in life. In the late 1980s approximately 21% 
of Norwegian women in the age group 20-44 years were regular users of combined 
oral contraceptives (38), and the proportion of users has subsequently increased 
(37).In Norway, the Wholesaler-based Drug Statistics report total COC consumption 
from the late 1960s, and the sales have increased from 84,790 DDD/day (defined daily 
dose) during 1970-79 to 159,256 DDD/day in the period 1990-99. The declining 
endometrial cancer rates at premenopausal age starting from the early 1980s may 
therefore, in part, be ascribed to COC exposure.  
 The increasing incidence of endometrial cancer in the last decade across all 
birth cohorts born after 1950 seems to be in conflict with the increased use of 
hormonal contraception. Therefore one may speculate whether other risk factors, such 
as increasing body mass may have contributed to the increase in rates. Body mass 
index is linearly associated with the risk of endometrial cancer (11). Overweight 
doubles the risk, and the risk may be up to 6-fold higher among very obese women 
(BMI 40). In Norway, population-based health surveys have documented increases in 
BMI during the 1980s and the 1990s (39;40). Mean body weight has increased in all 
age groups younger than 70 years, and the largest increase (7.3 kg) has been 
observed in women 20-29 years old. The consistent increase in body mass has been 
observed since 1985, and the proportion of obese (BMI 30) women in the age group 
20-29 years had tripled between the two surveys (3.7% vs. 11.9%). The most recent 
data (2000-03) from five Norwegian counties suggest that body mass continues to 
increase (41).  
 The recent increase in endometrial cancer incidence among women at 
premenopausal age coincides the strong increase in BMI in young women. The 
increased use of COCs may have contributed to an attenuation of an underlying 
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endometrial cancer epidemic caused by an increasing BMI in the population. A similar 
incidence increase has been observed in Finland, but not in Sweden. Also in Finland, 
mean BMI has increased in women younger than 30 years over the last 20 years (42), 
whereas in Sweden, an increase in mean BMI has not been observed (43;44).  
 The impact of BMI may be strongest for endometrioid adenocarcinoma (45), but 
few, if any studies have assessed the association of risk factors with different 
histological subtypes of endometrial cancer. We studied endometrial cancer as a 
single entity, and could not address the possibility that relevant risk factors may have 
different impact on different histological subtypes. 
 Previous predictions of endometrial cancer incidence in Norway were based on 
observations until 1997, and the results predicted a stabilization of rates thereafter 
(46). For the Nordic countries combined, a decline by 15% from 1993-1997 to 2018-
2022 has been predicted. Our analyses suggest that previous predictions were too 
conservative, and based on attenuated future trends (scenario A) we predict a 
continuing increase of 57% until 2025 compared to the observed rate in 2005. This 
scenario implies a decreased exposure to underlying risk factors over time. There are 
to date no studies that have evaluated if the risk increase due to BMI depends on age 
or duration of exposure. If the BMI effect depends on duration, the full BMI effect is yet 
to be seen. The less optimistic scenario B in this study that predicts higher rates of 
endometrial cancer incidence implies unchanged trends in exposure to underlying risk 
factors in the years beyond the observation period. It is in accordance with our 
previous finding that even a modest increase in population body mass will lead to an 
increase in endometrial cancer incidence (11). We therefore believe this scenario may 
provide a more realistic prediction of future endometrial cancer incidence should 
recent trends hold into the future. There are to date no reliable predictions of the 
development of BMI in Norway, but an increasing and substantial proportion of 
adolescents are overweight or obese (47). The proportion of endometrial cancers due 
to obesity in Europe has been estimated to about 40% (48), and by preventing obesity, 
a considerable proportion of endometrial cancer cases could be avoided.  
 In conclusion, this study provides evidence of a consistent increase in the 
incidence of endometrial cancer during the last 50 years. The increase has been more 
pronounced in postmenopausal women, but in the last decade the same trend has 
been observed in pre-and perimenopausal women. Our long-term predictions imply 
that the burden of endometrial cancer will continue to increase in the forthcoming 
 12
decades. Further research that provides a better appreciation of the underlying risk 
factors and their prevention will therefore remain a major objective in coming years. 
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Table 1: Endometrial cancer incidence in Norway: numbers of new cases, person-
years and cumulative risk 1988-92 and 2003-7, and estimated annual 
percentage change 1988-1997 and 1998-2007 for ages 0-79, 0-54 and 55-
79.  
 
 1988-92 2003-07 1988-1997 1998-2007 
Age 
Group 
Cases 
 
Person- 
Years+ 
CR* 
 
Cases 
 
Person- 
years+ 
CR* 
 
EAPC** 
 
EAPC** 
0-79 370 2.02 1.85 518 2.17 2.49 1.7 (0.5, 2.8) 1.7 (0.7, 2.7)
0-54   87 1.54 0.39 113 1.67 0.37 -0.6 (-2.3, 2.2) 1.7 (-0.4, 3.9)
55-79 283 0.48 1.46 404 0.50 2.12 2.1 (0.9, 3.4) 1.7 (0.6, 2.8)
+ per million 
* CR: cumulative risk  
** EAPC: estimated annual percentage change based on a log-linear model with year and age. Due to small numbers in the 
youngest age groups, EAPC in 0-79 and 0-54 are based on data for ages 25-79 and 25-54, respectively. 
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Table 2: Analysis of deviance for nested APC models, Norway 1953-2007 
 
Model df* Residual deviance Effect tested df* Deviance P(>|Chi|)
Age 50 1428.7
  
 Drift 1 1273.5 <0.01
Age-Drift 49 155.2
  
 
Non-linear 
Cohort 13 83.7 <0.01
Age-Cohort 36 71.5
  
 
Non-linear 
Period 9 44.9 <0.01
Age-Period-
Cohort** 
27 26.6
  
 
Non-linear 
Cohort -13 -120.6 <0.01
Age-Period 40 147.2
  
 
Non-linear 
Period -9 -8.1 0.53
Age-Drift 49 155.2
  
 
* degrees of freedom 
** Best-fitting APC model on the grounds of parsimony 
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Table 3: Predicted mean annual numbers of endometrial incidence cases 2015 and 
2025 by age group compared with the mean annual numbers observed in 
2005, and for all-ages incidence, relative changes due to changing risk and 
changing demographics (population aging and growth). Predictions 2008-27 
were obtained based on two scenarios A and B (see Material and Methods) 
on fitting APC models to the observed time trends 1988-2007. 
 
 
Age group observed 2005*
(% of total)
predicted 2015** 
(% of total) 
predicted 2025+ 
(% of total)
Scenario A    
All ages 647 873 1016
Difference from 2005 (% change) 
(% change in risk / demographics) 
+226 (35%) 
(18% / 17%) 
+369 (57%) 
(22% / 35%)
Ages 0-54 (% of total) 113 (17%) 147 (17%) 182 (18%)
Ages 55-79 (% of total) 419 (65%) 577 (66%) 614 (60%)
Ages 80+ (% of total) 115 (18%) 150 (17%) 220 (22%)
Scenario B  
All ages 647 905 1257
Difference from 2005 (% change) 
(% change in risk / demographics) 
+258 (40%) 
(23% / 17%) 
+609 (95%) 
(60% / 35%)
Ages 0-54 (% of total) 113 (17%) 153 (17%) 234 (19%)
Ages 55-79 (% of total) 419 (65%) 597 (66%) 757 (60%)
Ages 80+ (% of total) 115 (18%) 155 (18%) 266 (21%) 
* mean annual observed cases 2003-7 
** mean annual predicted cases 2013-17 
+ mean annual predicted cases 2023-25  
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Legend to Figures 
 
Figure 1: Trends in age-standardized (World) incidence rates of endometrial cancer versus 
calendar period in four Nordic countries by sex and menopausal status (aged 0-54 and 55-
79). Rates are presented as five-year moving averages. Source: NORDCAN (22) 
 
Figure 2: Observed trends in the incidence of endometrial cancer in Norway 1953-2007. 
Rates are presented as rates versus birth cohort by age (5-year age groups indicated) and 
calendar period cohort by age. 
 
Figure 3: Age, period and cohort effects, based on Holford’s approach for endometrial 
cancer, Norway 1953-2007, ages 35-79. Two sets of estimates are based on the full APC 
model assuming either a linear slope of zero for calendar period (red line), or for birth cohort 
(blue line). 
 
Figure 4: Observed (1953-2007) and predicted (2008-2027) age-standardized (World) 
ratesbased on an APC model fitted to the period 1988-2007 on the basis of two scenarios 
regarding the future linear trend. Rates are based on five-year aggregates for all ages. 
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